Emerging Growth Conference 88 December 11, 2025 9:05 AM ESTCompany ParticipantsJean-Marie Clouet - Vice President ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...
IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
In recent days, Rocket Companies participated in high-profile presentations at both the Stephens Annual Investment Conference and Deutsche Bank's Financial Services IRO Summit, highlighting its ...